Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia.
- Mechanism
- Curator reviewed
Rescinnamine Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
- Primary indication
- For the treatment of hypertension.Curator reviewed
- Formula / weight
- C35H42N2O9 · 634.716 g/mol (avg)
Resolves to
SZLZWPPUNLXJEA-QEGASFHISA-NSMILES[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2What you can answer from here — as of September 13, 2026
Which drugs share a target with Rescinnamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account